Immunosuppressive Treatment Results in Patients with Primary IgA Nephropathy in Turkiye; the Data from TSN-GOLD Working Group

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2024 Apr 18

PMID 38637275

Authors

Aysegul Oruc

Abdullah Sumnu

Aydin Turkmen

Taner Basturk

Egemen Cebeci

Kenan Turgutalp

Hakki Cetinkaya

Muge Uzerk Kibar

Nurhan Seyahi

Erhan Tatar

Metin Ergul

Ulver Derici

Mehmet Deniz Ayli

Musa Pinar

Betul Bakar

Rumeyza Kazancioglu

Abdulmecit Yildiz

Ahmet Burak Dirim

Zulfukar Yilmaz

Kultigin Turkmen

Onur Tunca

Mehmet Koc

Sim Kutlay

Hasan Micozkadioglu

Alper Azak

Burcu Boztepe

Sedat Ustundag

Seda Safak Ozturk

Abdulkadir Unsal

Serhat Karadag

Gulizar Sahin

Ezgi Cosgun Yenigun

Necmi Eren

Mustafa Gullulu

Meltem Gursu

Savas Ozturk

Affiliations

Soon will be listed here.

Abstract

Background: Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye.

Method: The data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 ± 12.5 years, follow-up 30 (3-218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed.

Results: Remission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% 66.7%, = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% 49%, = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08-1.89, = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51-0.91, = 0.008) and combined IST (HR 0.66, 95% CI 0.49-0.91, = 0.009) were found to be significant regarding remission.

Conclusion: CS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.

References

Haaskjold Y, Lura N, Bjorneklett R, Bostad L, Knoop T, Bostad L . Long-term follow-up of IgA nephropathy: clinicopathological features and predictors of outcomes. Clin Kidney J. 2023; 16(12):2514-2522. PMC: 10689167. DOI: 10.1093/ckj/sfad154. View

Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M . After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020; 98(4):1044-1052. DOI: 10.1016/j.kint.2020.04.046. View

Novak J, Rizk D, Takahashi K, Zhang X, Bian Q, Ueda H . New Insights into the Pathogenesis of IgA Nephropathy. Kidney Dis (Basel). 2015; 1(1):8-18. PMC: 4640461. DOI: 10.1159/000382134. View

Hou J, Le W, Chen N, Wang W, Liu Z, Liu D . Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. Am J Kidney Dis. 2017; 69(6):788-795. DOI: 10.1053/j.ajkd.2016.11.027. View

Cambier A, Troyanov S, Tesar V, Coppo R . Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the Oxford classification. Nephrol Dial Transplant. 2022; 37(6):1195-1197. DOI: 10.1093/ndt/gfac025. View

Natale P, Palmer S, Ruospo M, Saglimbene V, Craig J, Vecchio M . Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020; 3:CD003965. PMC: 7066485. DOI: 10.1002/14651858.CD003965.pub3. View

Zhao H, Li Y, Sun J, Xu G, Wang C, Zhou S . Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting. Clin J Am Soc Nephrol. 2023; 18(9):1186-1194. PMC: 10564371. DOI: 10.2215/CJN.0000000000000215. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B . Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. J Am Soc Nephrol. 2017; 29(1):317-325. PMC: 5748925. DOI: 10.1681/ASN.2017060713. View

10.

Lv J, Zhang H, Wong M, Jardine M, Hladunewich M, Jha V . Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2017; 318(5):432-442. PMC: 5817603. DOI: 10.1001/jama.2017.9362. View

11.

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B . Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015; 373(23):2225-36. DOI: 10.1056/NEJMoa1415463. View

12.

Manno C, Torres D, Rossini M, Pesce F, Schena F . Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009; 24(12):3694-701. DOI: 10.1093/ndt/gfp356. View

13.

Zhang Y, Lv J, Wong M, Zhang H, Perkovic V . Glucocorticoids for IgA nephropathy-pro. Kidney Int. 2023; 103(4):666-669. DOI: 10.1016/j.kint.2023.01.018. View

14.

Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh A . Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2008; 53(1):26-32. DOI: 10.1053/j.ajkd.2008.07.029. View

15.

Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi G, Altieri P . Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2003; 15(1):157-63. DOI: 10.1097/01.asn.0000103869.08096.4f. View

16.

Hou F, Xie D, Wang J, Xu X, Yang X, Ai J . Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. JAMA Netw Open. 2023; 6(2):e2254054. DOI: 10.1001/jamanetworkopen.2022.54054. View

17.

Lv J, Xu D, Perkovic V, Ma X, Johnson D, Woodward M . Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012; 23(6):1108-16. PMC: 3358763. DOI: 10.1681/ASN.2011111112. View

18.

Turkmen A, Sumnu A, Cebeci E, Yazici H, Eren N, Seyahi N . Epidemiological features of primary glomerular disease in Turkey: a multicenter study by the Turkish Society of Nephrology Glomerular Diseases Working Group. BMC Nephrol. 2020; 21(1):481. PMC: 7666482. DOI: 10.1186/s12882-020-02134-8. View

19.

Wyatt R, Julian B . IgA nephropathy. N Engl J Med. 2013; 368(25):2402-14. DOI: 10.1056/NEJMra1206793. View

20.

Coppo R, DAmico G . Factors predicting progression of IgA nephropathies. J Nephrol. 2005; 18(5):503-12. View